After Inflectra’s approval, challenges remain for biosimilars

Now that the Food and Drug Administration has approved Inflectra as the first biosimilar version of the anti–tumor necrosis factor-alpha agent Remicade, rheumatologists and patient advocacy groups...
Source: Rheumatology News - Category: Rheumatology Source Type: research